Panasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing Technology
The Californer/10277180

~ Shinobi Therapeutics, a biotechnology company, has announced a new partnership with Panasonic Holdings Corp and Kyoto University's Center for iPS Cell Research and Application (CiRA) to develop a more efficient and cost-effective method of producing iPS-T cell therapies.

The collaboration between these organizations aims to create a novel manufacturing platform that will make iPS-T cell therapies more accessible to the general population. Yuki Kusumi, Representative Director and President of Panasonic Holdings Corporation, stated that their goal is to produce safe cells for therapies at the lowest possible cost. He also emphasized the importance of maintaining safety and efficacy while reducing production time and costs.

Cell therapies have shown great potential in treating blood cancers and other difficult-to-treat diseases. However, the high manufacturing costs make these therapies out of reach for many patients worldwide. Shinobi's iPS-T cell technology, which is based on a decade's worth of iPSC research conducted by co-founder Shin Kaneko at CiRA using iPSCs created by Nobel laureate Shinya Yamanaka, will be utilized in this partnership to support the development of a closed-system manufacturing device created by Panasonic.

More on The Californer

• California celebrates Genentech's 50th anniversary
• Sonnenblick-Eichner Company Arranges $26 Million Loan to Refinance San Francisco area hotel
• Vietnam Must End Human Rights Violations—Not Just "Walk the Talk"
• Poyst Launches Local Marketplace Platform to Help Communities Discover, Build, and Sell Locally
• Green Office Partner Strengthens Global Operations with Mexico-Based DigitalVAAR Partnership

Shin Kaneko, co-founder at Shinobi, expressed his excitement about the advancements in iPS cell production and genetic modification for immune evasion. He believes that the automated cultivation device developed through this joint research will significantly accelerate progress towards providing state-of-the-art regenerative killer T cell therapy for every patient.

The partnership will leverage Panasonic's expertise in manufacturing to create a new method of producing iPS-T cell therapies in a closed-system process. The first phase of this collaboration is expected to be completed by April 2025 when the companies plan to release the initial prototype.

Dan Kemp, CEO at Shinobi, acknowledged that while cell therapies have the potential to revolutionize patient care for various diseases, there are still challenges in terms of manufacturability and accessibility. He expressed gratitude for the opportunity to work with renowned partners in both the academic and industry sectors as they strive to make cell therapies accessible to all patients in need.

This partnership between Shinobi Therapeutics, Panasonic Holdings Corp, and Kyoto University's CiRA is a significant step towards making iPS-T cell therapies more accessible and affordable for patients worldwide. With the combined expertise of these organizations, it is hoped that this new manufacturing platform will pave the way for a future where cell therapies are within reach for all who need them.

---

Show All News | Disclaimer | Report Violation